mResell levererade fortsatt stark tillväxt i Q2’26.
Botnia Gold går in i andra halvåret med förbättrade produktionsförutsättningar och preliminärt posit...
Lytix Biopharma's second-quarter 2026 report was dominated by the FDA's feedback that it raises no o...
Redeye return with an update after IRLAB's Q2 report, which contained few surprises.
Kvartalet var i stort sett i linje med våra förväntningar avseende intäkter och bruttoresultat, meda...
Redeye updates on GiG after Q2-results, which were softer than expected, while the main news in the ...
Following the strong semaglutide data reported earlier this year, Nanexa’s Q2 update points to conti...
Redeye updates on NextCell following its Q2 2026 report, which financially aligned closely to our pr...
Redeye provides a research update following the Q2 report recently published by OncoZenge.
Alligator delivered an uneventful second quarter, in line with expectations for a pre-revenue biotec...
Redeye states that the Q2 report showed a soft quarter on headline figures, largely as flagged by ma...
Curasight had a small delay in its clinical programme, so the topline of both ph1 uTREAT and ph2 uTR...
Redeye provides a research update on Faron following the company’s recent H1 report.
The FDA yesterday approved Revolution Medicines' Rasonque (daraxonrasib) for second-line-plus metast...
Redeye provides a review following AcouSort's Q2 2026 report, which, apart from slight deviations fr...
BONESUPPORT announced that the FDA has requested additional biocompatibility data for CERAMENT V, ex...
SynAct’s Q226 results marked a strategically important period in defining resomelagon’s clinical and...
* H1 above driven by strong margins and cost control.
Redeye comments on Fable Media Group's Q2 2026 results, bang in line with our estimates across the b...
Eolus’ Q2 report was broadly in line with our expectations, with soft financials largely reflecting ...
